We are live on ! Find out more
SLRN

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

122 hedge funds and large institutions have $430M invested in ACELYRIN in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 11

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

12% more capital invested

Capital invested by funds: $384M → $430M (+$46.6M)

9% more funds holding

Funds holding: 112122 (+10)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.43% less ownership

Funds ownership: 87.84%87.41% (-0.43%)

43% less call options, than puts

Call options by funds: $154K | Put options by funds: $272K

Holders
122
Holders Change
+10
Holders Change %
+8.93%
% of All Funds
1.75%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
22
Increased
44
Reduced
35
Closed
11
Calls
$154K
Puts
$272K
Net Calls
-$118K
Net Calls Change
-$107K
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$51.4M +$36.6M +7,079,539 +211%
ACMC
2
AyurMaya Capital Management Company
New Hampshire
$46M
Citadel Advisors
3
Citadel Advisors
Florida
$32.2M -$4.58M -887,258 -12%
BlackRock
4
BlackRock
New York
$29.5M +$3.68M +713,000 +14%
Millennium Management
5
Millennium Management
New York
$27.1M +$4.36M +845,116 +18%
Vanguard Group
6
Vanguard Group
Pennsylvania
$20.1M -$3.49M -676,412 -14%
O
7
OrbiMed
New York
$19.7M
VP
8
venBio Partners
California
$19M
TCM
9
Tybourne Capital Management
Hong Kong
$14.3M
GA
10
General Atlantic
New York
$14.2M
BOCH
11
Blue Owl Capital Holdings
New York
$13.8M -$682K -132,082 -5%
SB
12
Samsara BioCapital
California
$12.4M
OM
13
Opaleye Management
Massachusetts
$9.34M +$1.62M +313,660 +20%
PAI
14
Palo Alto Investors
California
$8.84M +$401K +77,715 +5%
Morgan Stanley
15
Morgan Stanley
New York
$8.81M +$2.76M +533,637 +43%
SL
16
Siren LLC
Connecticut
$8.53M +$8.93M +1,729,665 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$8.14M +$2.01M +388,631 +31%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$6.54M -$792K -153,465 -10%
SC
19
Stempoint Capital
New York
$6.5M +$6.8M +1,317,854 New
State Street
20
State Street
Massachusetts
$6.28M +$599K +116,094 +10%
RI
21
RTW Investments
New York
$4.82M
JP Morgan Chase
22
JP Morgan Chase
New York
$4.19M -$9.02M -1,747,642 -67%
KCM
23
Kynam Capital Management
New Jersey
$4.18M +$82.9K +16,056 +2%
IC
24
Ikarian Capital
Texas
$3.34M -$4.12M -798,000 -54%
Charles Schwab
25
Charles Schwab
California
$3.01M +$1.41M +273,604 +81%

SLRN Hedge Fund Activity: Q3 2024 in Review

122 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q3 2024, worth a combined $430M — up 12% from $384M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new SLRN positions and 11 closed out — a net gain of 11 holders — while 44 added to existing stakes and 35 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $36.6M. The largest seller was Fidelity Investments, cutting an estimated $23.7M.

  • 122 institutional investors held ACELYRIN (SLRN) as of Q3 2024, up from 112 in Q2 2024.
  • Funds reported $430M of ACELYRIN stock for Q3 2024, up 12% quarter-over-quarter.
  • 22 funds opened new ACELYRIN positions in Q3 2024 and 11 closed out, a net change of +11 holders.
  • The largest ACELYRIN buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $36.6M added.
  • The largest ACELYRIN seller in Q3 2024 was Fidelity Investments, an estimated $23.7M sold.

Based on aggregated 13F filings for Q3 2024.